HHS Employee Layoffs Temporarily Reversed by Judge: A federal judge has temporarily blocked the Trump administration’s planned layoffs of roughly 5,200 probationary employees at the Department of Health and Human Services (HHS). The layoffs were part of a broader agency restructuring effort led by Health Secretary Robert F. Kennedy Jr. The judge’s ruling follows a lawsuit from affected employees and unions who argued the layoffs violated federal workforce protections and due process. The injunction halts job terminations until the court can fully assess the legality of the administration’s actions. The decision is a significant pause in HHS’s reorganization, which includes potential consolidation or elimination of various public health offices.
Key Takeaways: Uncertainty remains around the future of federally supported public health resources and programs. Leaders should plan for disruptions that could impact hospital operations and consider how they can advocate for the resources they need.
Proposed Cuts to CDC’s HIV Prevention Funding: The Trump administration is considering significant reductions to the Centers for Disease Control and Prevention’s (CDC) domestic HIV prevention budget. This includes funding for initiatives like the Pre-Exposure Prophylaxis (PrEP) program, which plays a crucial role in preventing HIV transmission. In 2023, the CDC allocated approximately $1.3 billion for the prevention of HIV, viral hepatitis, and other sexually transmitted infections. Advocates express concern that such cuts could undermine efforts to combat HIV, particularly affecting marginalized communities. The move would seem to run counter to one of Trump’s most high-profile first-term priorities. In 2019, he launched the Ending the HIV Epidemic initiative with the goal of reducing new HIV cases in the U.S. 90 percent by 2030.
Key Takeaways: Public health leaders should be preparing for a reduced access to HIV prevention programs, tools, and treatment–especially PrEP. Health leaders should Assess internal capacity to maintain or expand HIV prevention services amid possible federal funding cuts and collaborate with local public health organizations to offset program losses.
Researchers Concerned about Proposed NIH Funding Cuts: Researchers and patients around the country are expressing concern over proposed National Institutes of Health (NIH) funding cuts, which could hinder medical advancements. The policy change would reduce indirect cost reimbursements from an average of 27-28% to 15%, impacting research expenses like equipment and salaries. Institutions such as the University of California system, Oklahoma Public University system, the University of Pennsylvania, Yale and the University of Connecticut, among many others, could face significant financial losses, potentially halting research and affecting local economies.
Key Takeaways: The impact on research and development of new treatments and technologies will be profound, so it is imperative to evaluate current and future reliance on NIH-funded research for strategic planning and diversify funding sources going forward.
Alabama Advances Regulations on Pharmacy Benefit Managers: Alabama lawmakers have advanced a bill to regulate pharmacy benefit managers (PBMs) to alleviate the financial strain on independent pharmacies. The legislation mandates that PBMs reimburse community pharmacies at rates comparable to those of the Alabama Medicaid Agency and bans “spread pricing,” where PBMs charge more to health plans than they pay to pharmacies. While proponents argue it will protect local pharmacies and reduce drug prices, opponents contend the bill’s requirements could lead to higher costs for small businesses and consumers. Legislation at the federal level to regulate PBMs stalled at the end of 2024, but a Federal Trade Commission lawsuit filed in September 2024 is ongoing. The PMB industry has responded and last week, Optum Rx, the PBM division of UnitedHealth Group, announced the elimination of annual reauthorization requirements for 80 drugs. This move aims to reduce overall pharmacy prior authorizations by more than 10%, addressing widespread patient frustration over delays and denials of care due to prior authorization processes.
Key Takeaways: While there may be short-term uncertainty in drug pricing structures could affect procurement strategies, there is the possibility of a reduction in patient medication delays due to PBM reform, particularly from Optum Rx’s authorization changes. Hospitals should use reduced prior authorization burdens to streamline inpatient-to-outpatient medication transitions.
On the Horizon
Department of Health and Human Services (HHS) Reorganization: The Trump administration is planning significant workforce reductions at the Department of Health and Human Services (HHS) under Health Secretary Robert F. Kennedy Jr. Agencies likely to be affected include the Office of Technology Policy, the Office of the National Coordinator for Health Information Technology, the Agency for Healthcare Research and Quality, the Health Resources and Services Administration, and the Administration for Children and Families. These changes could impact health research and technology initiatives nationwide. Agencies are directed to submit plans by March 13 for what is known as a reduction in force, which would not only lay off employees but eliminate the position altogether. By April 14 agencies are expected to outline how they will consolidate management, become more efficient and potentially relocate offices to parts of the country that are less expensive than Washington. Agencies have a September 30 deadline for implementation.
Key Takeaways: Anticipate disruption to key agencies supporting health IT, quality improvement, and workforce development. There may also be delays or changes in grant programs, data support, and national quality initiatives as well as possible geographic shifts in federal support services away from Washington D.C., affecting accessibility.